Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237309 · ClinicalTrials.gov registry record · Phase 2
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT06237309 is a Phase 2 study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 89 participants.
The verdict
NCT06237309, a Phase 2 study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should). The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Interventions
- DRUG Placebo
- DRUG REGN5381
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2024-04-11 |
| Est. Completion | 2025-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06237309
The ClinicalTrials.gov registry entry for NCT06237309 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06237309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06237309 about?
NCT06237309 is a clinical study titled "REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction". This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should). The aim of the study is to see how safe, tolerable, and effective the stu...
What is the current status of trial NCT06237309?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2024-04-11. Estimated completion is 2025-12-29.
What interventions are being tested in trial NCT06237309?
The interventions under investigation include: Placebo (DRUG), REGN5381 (DRUG).
Who is sponsoring clinical trial NCT06237309?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.